Roche withdraws US approval for Tecentriq in mTNBC
Metastatic triple-negative breast cancer treatment failed to meet PFS primary endpoint
Read More
Tag: Tecentriq
Tecentriq wins FDA priority review for certain early NSCLC patients
Tecentriq is first and only cancer immunotherapy with positive Phase III results in adjuvant lung cancer setting
Read More
Tecentriq, Kesimpta lead latest SMC decisions
SMC was unable to accept Pfizer’s Vyndaqel for use in patients with transthyretin amyloidosis
Read More
NICE recommends Tecentriq for first-line NSCLC
Tecentriq is indicated for adults with metastatic NSCLC if their tumours have PD-L1 expression on at least 50% of tumour cells or 10% of tumour-infiltrating immune cells
Read More
Tecentriq approved for first-line metastatic NSCLC
Checkpoint inhibitor specifically approved for patients with high PD-L1 expression
Read More
Roche’s Tecentriq improves disease-free survival in early lung cancer
Tecentriq is approved in five lung cancer indications currently
Read More
Roche withdraws US indication for Tecentriq in bladder cancer
Tecentriq failed to improve overall survival in post-marketing study
Read More
Roche’s Tecentriq/Avastin combo improves survival in liver cancer
Updated analysis is from the Phase III IMbrave150 study
Read More
Waylivra, Tecentriq and more accepted by SMC
Akcea’s Waylivra approved via ultra-orphan pathway
Read More
Tecentriq misses mark in ovarian cancer trial
The drug did not extend progression-free survival in patients with newly diagnosed advanced stage ovarian cancer
Read More
Roche’s Tecentriq shows promise in early triple-negative breast cancer
Less patients who received the Tecentriq combination before surgery had evidence of tumour tissue detectable at the time of surgery
Read More
Roche’s Tecentriq/Avastin combo wins US approval
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer
Read More
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
